Cargando…
Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
The newly emerged Omicron SARS-CoV-2 has several distinct sublineages including BA.1, BA.2, and BA.3. BA.1 accounts for the initial surge and is being replaced by BA.2, whereas BA.3 is at a low prevalence at this time. Here we report the neutralization of BNT162b2-vaccinated sera (collected 1 month...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225806/ https://www.ncbi.nlm.nih.gov/pubmed/35739094 http://dx.doi.org/10.1038/s41467-022-30681-1 |
_version_ | 1784733702490685440 |
---|---|
author | Kurhade, Chaitanya Zou, Jing Xia, Hongjie Cai, Hui Yang, Qi Cutler, Mark Cooper, David Muik, Alexander Jansen, Kathrin U. Xie, Xuping Swanson, Kena A. Shi, Pei‑Yong |
author_facet | Kurhade, Chaitanya Zou, Jing Xia, Hongjie Cai, Hui Yang, Qi Cutler, Mark Cooper, David Muik, Alexander Jansen, Kathrin U. Xie, Xuping Swanson, Kena A. Shi, Pei‑Yong |
author_sort | Kurhade, Chaitanya |
collection | PubMed |
description | The newly emerged Omicron SARS-CoV-2 has several distinct sublineages including BA.1, BA.2, and BA.3. BA.1 accounts for the initial surge and is being replaced by BA.2, whereas BA.3 is at a low prevalence at this time. Here we report the neutralization of BNT162b2-vaccinated sera (collected 1 month after dose 3) against the three Omicron sublineages. To facilitate the neutralization testing, we have engineered the complete BA.1, BA.2, or BA.3 spike into an mNeonGreen USA-WA1/2020 SRAS-CoV-2. All BNT162b2-vaccinated sera neutralize USA-WA1/2020, BA.1-, BA.2-, and BA.3-spike SARS-CoV-2s with titers of >20; the neutralization geometric mean titers (GMTs) against the four viruses are 1211, 336, 300, and 190, respectively. Thus, the BA.1-, BA.2-, and BA.3-spike SARS-CoV-2s are 3.6-, 4.0-, and 6.4-fold less efficiently neutralized than the USA-WA1/2020, respectively. Our data have implications in vaccine strategy and understanding the biology of Omicron sublineages. |
format | Online Article Text |
id | pubmed-9225806 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-92258062022-06-24 Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine Kurhade, Chaitanya Zou, Jing Xia, Hongjie Cai, Hui Yang, Qi Cutler, Mark Cooper, David Muik, Alexander Jansen, Kathrin U. Xie, Xuping Swanson, Kena A. Shi, Pei‑Yong Nat Commun Article The newly emerged Omicron SARS-CoV-2 has several distinct sublineages including BA.1, BA.2, and BA.3. BA.1 accounts for the initial surge and is being replaced by BA.2, whereas BA.3 is at a low prevalence at this time. Here we report the neutralization of BNT162b2-vaccinated sera (collected 1 month after dose 3) against the three Omicron sublineages. To facilitate the neutralization testing, we have engineered the complete BA.1, BA.2, or BA.3 spike into an mNeonGreen USA-WA1/2020 SRAS-CoV-2. All BNT162b2-vaccinated sera neutralize USA-WA1/2020, BA.1-, BA.2-, and BA.3-spike SARS-CoV-2s with titers of >20; the neutralization geometric mean titers (GMTs) against the four viruses are 1211, 336, 300, and 190, respectively. Thus, the BA.1-, BA.2-, and BA.3-spike SARS-CoV-2s are 3.6-, 4.0-, and 6.4-fold less efficiently neutralized than the USA-WA1/2020, respectively. Our data have implications in vaccine strategy and understanding the biology of Omicron sublineages. Nature Publishing Group UK 2022-06-23 /pmc/articles/PMC9225806/ /pubmed/35739094 http://dx.doi.org/10.1038/s41467-022-30681-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Kurhade, Chaitanya Zou, Jing Xia, Hongjie Cai, Hui Yang, Qi Cutler, Mark Cooper, David Muik, Alexander Jansen, Kathrin U. Xie, Xuping Swanson, Kena A. Shi, Pei‑Yong Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine |
title | Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine |
title_full | Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine |
title_fullStr | Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine |
title_full_unstemmed | Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine |
title_short | Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine |
title_sort | neutralization of omicron ba.1, ba.2, and ba.3 sars-cov-2 by 3 doses of bnt162b2 vaccine |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225806/ https://www.ncbi.nlm.nih.gov/pubmed/35739094 http://dx.doi.org/10.1038/s41467-022-30681-1 |
work_keys_str_mv | AT kurhadechaitanya neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine AT zoujing neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine AT xiahongjie neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine AT caihui neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine AT yangqi neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine AT cutlermark neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine AT cooperdavid neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine AT muikalexander neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine AT jansenkathrinu neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine AT xiexuping neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine AT swansonkenaa neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine AT shipeiyong neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine |